Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a ...
The US FDA has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback